Show simple item record

dc.contributor.authorJubeh, Buthaina
dc.contributor.authorBreijyeh, Zeinab
dc.contributor.authorKaraman, Rafik
dc.date.accessioned2020-07-21T10:33:45Z
dc.date.available2020-07-21T10:33:45Z
dc.date.issued2020-03-28
dc.identifier.issn1420-3049
dc.identifier.urihttps://dspace.alquds.edu/handle/20.500.12213/5699
dc.description.abstractBacterial resistance to present antibiotics is emerging at a high pace that makes the development of new treatments a must. At the same time, the development of novel antibiotics for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to combat resistance, time and e ort preserving approaches, like the prodrug approach, are most needed. Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before eliciting their pharmacological e ects. A prodrug strategy can be used to revive drugs discarded due to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug. In this article, we review the up-to-date implementation of prodrugs to develop medications that are active against drug-resistant bacteria.en_US
dc.description.sponsorshipAcknowledgments: The authors would like to thank Al-Quds University-Scientific Research O ce for covering the publication fees for this review article.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.subjectprodrugsen_US
dc.subjectbiotransformationen_US
dc.subjecttargetingen_US
dc.subject-lactam antibioticsen_US
dc.subject-lactamasesen_US
dc.subjectpathogensen_US
dc.subjectresistanceen_US
dc.titleAntibacterial Prodrugs to Overcome Bacterial Resistanceen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record